London, UK; Brentwood, TN, US: 29 November - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that today, application has been made to the UK Listing Authority and the London Stock Exchange for 253,211 ordinary shares of 2p each in the Company (the "Shares") to be admitted to trading on the Official List and to trading on London Stock Exchange's main market. The Shares have been allotted pursuant to the conversion of EUR300,000 in nominal value of convertible loan notes (the "Notes") issued to CoVaccine BV on 2 November 2007.
